Abstract
THE normal cellular homologue of the acutely transforming oncogene v-ra/is c-raf-l, which encodes a serine/threonine protein kinase that is activated by many extracellular stimuli1. The physiological substrates of the protein c-Raf-1 are unknown. The mitogen-activated protein (MAP) kinases ErkI and 2 are also activated by mitogens through phosphorylation of Erk tyrosine and threonine residues catalysed by a protein kinase of relative molecular mass 50,000, MAP kinase-kinase (MAPK-K)2–7. Here we report that MAPK-K as well as Erkl and 2 are constitutively active in v-raf-transformed cells. MAPK-K partially purified from v-raf-transformed cells or from mitogen-treated cells3 can be deactivated by phosphatase 2A. c-Raf-1 purified after mitogen stimulation can reactivate the phosphatase 2A-inactivated MAPK-K over 30-fold in vitro. c-Raf-1 reactivation of MAPK-K coincides with the selective phosphorylation at serine/threonine residues of a polypeptide with Mr 50,000 which coelutes precisely on cation-exchange chromatography with the MAPK-K activatable by c-Raf-1. These results indicate that c-Raf-1 is an immediate upstream activator of MAPK-K in vivo. To our knowledge, MAPK-K is the first physiological substrate of the c-raf-l protooncogene product to be identified.
This is a preview of subscription content
Access options
Subscribe to Journal
Get full journal access for 1 year
204,58 €
only 4,01 € per issue
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
References
Rapp, U. R. Oncogene 6, 495–500 (1991).
Ahn, N. G., Weiel, J. E., Chan, C. P. & Krebs, E. G. J. biol. Chem. 265, 11487–11494 (1990).
Kyriakis, J. M., Brautigan, D. L., Ingelbritsen, T. S. & Avruch, J. J. biol. Chem. 266, 10043–10046 (1991).
Anderson, N. G., Maller, J. L., Tonks, N. K. & Sturgill, T. W. Nature 343, 651–653 (1990).
Ahn, N. G., et al. J. biol. Chem. 266, 4220–4227 (1991).
Gomez, N. & Cohen, P. Nature 353, 170–173 (1991).
Allemain, G. L., Her, J.-H., Wu, J., Sturgill, T. W. & Weber, M. J. Molec. cell. Biol. 12, 2222–2229 (1992).
Rapp, U. R., Reynolds, F. H. & Stephenson, J. R. J. Virol. 45, 914–924 (1983).
Matsuda, S. et al. EMBO J. 11, 973–982 (1992).
Pulverer, B. J., et al. Nature 353, 670–674 (1991).
Sturgill, T. W., Ray, L. B., Erikson, E. & Maller, J. L. Nature 334, 715–718 (1988).
Dent, P. et al. Nature 348, 302–308 (1990).
Anderson, N. G. et al. Biochem. J. 277, 573–576 (1991).
Lee, R.-M., Cobb, M. H. & Blackshear, P. J. J. biol. Chem. 267, 1088–1092 (1992).
Downward, J. et al. Nature 346, 719–723 (1990).
Burgering, B. M. et al. EMBO J. 10, 1103–1109 (1991).
Satoh, T., Nakafuku, M., Miyajima, A. & Kaziro, Y. Proc natn. Acad. Sci. U.S.A. 88, 3314–3318 (1991).
Leevers, S. J. & Marshall, C. J. EMBO J. 11, 569–574 (1992).
Bruder, J. T., Heidecker, G. & Rapp, U. R. Genes Dev. 6, 545–556 (1992).
Troppmair, J. et al. Oncogene (in the press).
Grove, J. R., Price, D. J., Goodman, H. M. & Avruch, J. Science 238, 530–533 (1987).
Hsi, E. D. et al. J. Biol. Chem. 264, 10836–10842 (1989).
Kyriakis, J. M. & Avruch, J. J. biol. Chem. 265, 17355–17363 (1990).
Takeda, M. et al. J. biol. Chem. 258, 10455–10463 (1988).
Jones, S. W., Erikson, R. L., Ingebritsen, V. M. & Ingebritsen, T. S. J. biol. Chem. 264, 7747–7753 (1989).
Kyriakis, J. M. & Avruch, J. Biochem. Biophys. Acta 1054, 73–82 (1990).
Author information
Affiliations
Rights and permissions
About this article
Cite this article
Kyriakis, J., App, H., Zhang, Xf. et al. Raf-1 activates MAP kinase-kinase. Nature 358, 417–421 (1992). https://doi.org/10.1038/358417a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/358417a0
Further reading
-
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
Journal of Hematology & Oncology (2020)
-
The Role of PI3K/Akt and ERK in Neurodegenerative Disorders
Neurotoxicity Research (2019)
-
The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance
Journal of Experimental & Clinical Cancer Research (2018)
-
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
Oncogene (2018)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.